Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Average Price Target of $38.57 According to Analysts

Shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) have received a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $38.57.

Several research firms have commented on SPTX. UBS Group downgraded shares of Seaport Therapeutics to a “sell” rating in a research note on Tuesday, June 9th. Weiss Ratings lowered Seaport Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Seaport Therapeutics in a report on Thursday, September 10th. Seaport Research Partners set a $46.00 target price on Seaport Therapeutics in a research note on Friday, September 25th. Finally, Wolfe Research assumed coverage on Seaport Therapeutics in a report on Tuesday, July 7th. They set a “hold” rating on the stock.

Institutional Trading of Seaport Therapeutics

A number of large investors have recently made changes to their positions in the company. TRV GP VI LLC acquired a new stake in shares of Seaport Therapeutics in the 2nd quarter valued at $44,769,742. Braidwell LP acquired a new position in shares of Seaport Therapeutics during the 2nd quarter worth about $10,860,000. Citadel Advisors LLC acquired a new position in shares of Seaport Therapeutics during the 2nd quarter worth about $4,152,000. The Manufacturers Life Insurance Company purchased a new position in shares of Seaport Therapeutics in the 2nd quarter valued at about $1,793,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Seaport Therapeutics in the 2nd quarter valued at about $1,629,000.

Seaport Therapeutics Stock Up 7.9%

NASDAQ:SPTX opened at $20.17 on Monday. Seaport Therapeutics has a 52 week low of $14.85 and a 52 week high of $28.38. The stock’s fifty day moving average price is $22.78. The firm has a market capitalization of $1.08 billion and a PE ratio of -1.66.

Seaport Therapeutics (NASDAQ:SPTX) last posted its earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($1.07). As a group, equities analysts predict that Seaport Therapeutics will post -4.52 earnings per share for the current fiscal year.

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company is working to advance treatments for conditions in areas such as psychiatry and neurology, with the goal of addressing significant limitations associated with existing therapies.

Seaport’s drug-development efforts are supported by its proprietary Glyph platform, which is designed to enable oral delivery of therapeutics that have historically required injection or infusion.